Carlyle and PAI Partners agree to sell Theramex to Cinven
- Carlyle and PAI Partners agreed to sell Theramex, a London-based pharmaceutical company focused on women's health, to Cinven.
- The transaction is expected to close in the first half of 2027.
- Theramex has more than doubled its EBITDA since its acquisition by the sellers in 2022.
- The business reaches more than six million patients in over 80 countries.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Carlyle Group Inc. published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.